Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,707.69
-11.1099-0.41%
Number of Gainers:42
Number of Losers:54
Number of Flat:2
PE:- -
High:2,721.80
Open:2,718.68
Low:2,700.73
Close:2,718.82
Volume:181.23M
Turnover:41.06B
Market Cap:49.53T
Float Cap:46.09T

Loading ...

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

European Payments Groups Join Forces to Challenge US Dominance

Reuters
·
Sep 30

Amazon Price Target Raised to $360.00/Share from $335.00 by Rosenblatt

Dow Jones
·
Sep 30

Apple Set to Launch Smart Home Hub with Voice Recognition and Recipe Lookup, Plus Personalized Interface Switching

Deep News
·
Sep 30

TSMC Reportedly Weighs Texas Expansion as Second Major U.S. Chip Hub

Stock News
·
Sep 30

Analysts’ Top Technology Picks: Braze (BRZE), Accenture (ACN)

TIPRANKS
·
Sep 30

KIDZ AI Plans Autonomous Fleet Operations Strategy Tied to Potential 500 Tesla Robotaxi Acquisition

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

IBM Study Shows 62% of CFOs Take on Enterprise AI Strategy Leadership

Reuters
·
Sep 30

US Equity Futures Mostly Flat Pre-Bell as Traders Await Key Inflation Report

MT Newswires Live
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Jazz Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Sep 30

Rimac Group Names Matthias Wich as CFO, Effective September 2026

Reuters
·
Sep 30

Abbott Launches Simplescreen™ Crc Blood Test, Joining Cologuard Plus® in Its Colorectal Cancer Screening Portfolio

THOMSON REUTERS
·
Sep 30